Giles Campion

Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands.

Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom.

Part of Sartorius AG, Albumedix Ltd. is a British science-driven company and recognized leader of albumin-enabled solutions. The private company, based in Nottingham, UK, was founded in 1984 with a mission to empower excellence. Albumedix has supported its life-science partners in delivering safe doses of clinical and marketed therapeutics. The company's solutions include the world's only USP-NF compliant recombinant human albumin, client-centric development and compliance services, and drug-enhancing technologies. By challenging the status quo and striving for more, Albumedix enables the development and commercialization of advanced therapies and next-generation biopharmaceuticals. Albumedix is the world leader in recombinant human albumin and has developed a portfolio of products known as Recombumin®. Founded in 1973, the CEO of Albumedix is Jonas S. Moller. The company was acquired by Sartorius Stedim Biotech SA on September 30, 2022, for $500.47 million.